Photodiagnosis and Photodynamic Therapy
Volume 2, Issue 4 , Pages 239-246 , December 2005

History of photodynamic therapy in Great Britain

  • D. Mitton
    • ,
  • R. Ackroyd, MD, FRCS

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 114 2261398; fax: +44 114 2261398.

References 

  1. Ackroyd R, et al. The history of photodetection and photodynamic therapy. Photochem Photobiol. 2001;74(5):656–669
  2. Finsen NF. Phototherapy. London: Arnold; 1901.
  3. Fitzpatrick TB, Pathak MA. Historical aspects of methoxsalen and other furocoumarins. J Invest Dermatol. 1959;32(2, Part 2):229–231
  4. Raab O. Uber die Wirkung fluoreszierender Stoffe auf Infusorien. Z Biol. 1900;39:524–546
  5. Prime J. Les accidentes toxiques par l’eosinate de sodium. Paris: Jouve and Boyer; 1900;
  6. von Trappeiner H, Jesionek A. Therapeutische Versuche mit fluoreszierenden Stoffen. Med Worchenschr. 1903;47:2042–2044
  7. von Trappeiner H, Jodlabauer A. Uber Wirkung der photodynamischen (fluorieszierenden) Stoffe auf Protozan und Enzyme. Dtsche Arch Klin Med. 1904;80:427–487
  8. von Trappeiner H, Jodebauer A. Die Sensibilisierende Wirkung fluorieszierender Substanzer. Gesammte Untersuchungen uber die photodynamische erscheinung. 1907: F. C. W. Vogel, Leipzig.
  9. Kessel D. Photodynamic therapy: from the beginning. Photodiagn Photodyn Ther. 2004;1:3–7
  10. Kato H, et al. The history of the study of photodynamic therapy (PDT) and photodynamic diagnosis (PDD) in the department of Surgery. Tokyo Medical University. Photodiagn Photodyn Ther. 2004;1(2):107–110
  11. Hinnen P, et al. Biochemical basis of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation: a study in patients with (pre)malignant lesions of the oesophagus. Br J Cancer. 1998;78(5):679–682
  12. van den Boogert J, et al. 5-Aminolaevulinic acid-induced protoporphyrin IX accumulation in tissues: pharmacokinetics after oral or intravenous administration. J Photochem Photobiol B. 1998;44(1):29–38
  13. Ackroyd R, et al. Ablation treatment for Barrett oesophagus: what depth of tissue destruction is needed?. J Clin Pathol. 1999;52(7):509–512
  14. Ackroyd R, et al. Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double-blind, randomised, placebo-controlled trial. Gut. 2000;47(5):612–617
  15. Kelty CJ, et al. Comparison of high-dose vs. low-dose 5-aminolevulinic acid for photodynamic therapy of Barrett's esophagus. Surg Endosc. 2004;18(3):452–458
  16. Kelty CJ, et al. Endoscopic ablation of Barrett's oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation. Aliment Pharmacol Ther. 2004;20(11–12):1289–1296
  17. Barr H, et al. Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet. 1996;348(9027):584–585
  18. Moghissi K, et al. The role of photodynamic therapy (PDT) in inoperable oesophageal cancer. Eur J Cardiothorac Surg. 2000;17(2):95–100
  19. Nuutinen PJ, et al. Distribution and photodynamic effect of disulphonated aluminium phthalocyanine in the pancreas and adjacent tissues in the Syrian golden hamster. Br J Cancer. 1991;64(6):1108–1115
  20. Chatlani PT, et al. Selective necrosis in hamster pancreatic tumours using photodynamic therapy with phthalocyanine photosensitization. Br J Surg. 1992;79(8):786–790
  21. Regula J, et al. Photodynamic therapy using 5-aminolaevulinic acid for experimental pancreatic cancer-prolonged animal survival. Br J Cancer. 1994;70(2):248–254
  22. Mlkvy P, et al. Distribution and photodynamic effects of meso-tetrahydroxyphenylchlorin (mTHPC) in the pancreas and adjacent tissues in the Syrian golden hamster. Br J Cancer. 1996;73(12):1473–1479
  23. Mikvy P, et al. Photodynamic therapy of a transplanted pancreatic cancer model using meta-tetrahydroxyphenylchlorin (mTHPC). Br J Cancer. 1997;76(6):713–718
  24. Bown SG, et al. Photodynamic therapy for cancer of the pancreas. Gut. 2002;50(4):549–557
  25. de Groen PC, et al. Biliary tract cancers. N Engl J Med. 1999;341(18):1368–1378
  26. Polydorou AA, et al. Palliation of proximal malignant biliary obstruction by endoscopic endoprosthesis insertion. Gut. 1991;32(6):685–689
  27. Ortner ME, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology. 2003;125(5):1355–1363
  28. Pereira SP, et al. Preliminary results of a phase II trial to examine the safety and efficacy of porfimer sodium photodynamic therapy (PDT) in locally advanced biliary tract carcinoma (BTC). ASCO Annual Meeting, 2005.
  29. Moghissi K, Dixon K, Hudson E. Photodynamic therapy (PDT) for bronchial carcinoma with use of a rigid bronchoscope. Laser Med Sci. 1991;7:381–385
  30. Moghissi K, Dixon K, Thorpe JA. A method for video assisted thorascopic photodynamictherapy. Int Cardiovasc Thorac Surg. 2003;2:373–375
  31. Moghissi K, et al. Photodynamic therapy (PDT) for lung cancer: the Yorkshire Laser Centre experience. Photodiagn Photodyn Ther. 2004;1:253–262
  32. Beatt KJ, Serruys PW, Hugenholtz PG. Restenosis after coronary angioplasty: new standards for clinical studies. J Am Coll Cardiol. 1990;15(2):491–498
  33. Schwartz RS, et al. Restenosis after balloon angioplasty. A practical proliferative model in porcine coronary arteries. Circulation. 1990;82(6):2190–2200
  34. Nyamekye I, et al. Photodynamic therapy of normal and balloon-injured rat carotid arteries using 5-amino-levulinic acid. Circulation. 1995;91(2):417–425
  35. Jenkins MP, et al. Intra-arterial photodynamic therapy using 5-ALA in a swine model. Eur J Vasc Endovasc Surg. 1998;16(4):284–291
  36. Jenkins MP, et al. Clinical study of adjuvant photodynamic therapy to reduce restenosis following femoral angioplasty. Br J Surg. 1999;86(10):1258–1263
  37. Mansfield RJ, et al. Long-term safety and efficacy of superficial femoral artery angioplasty with adjuvant photodynamic therapy to prevent restenosis. Br J Surg. 2002;89(12):1538–1539
  38. Muller PJ, Wilson BC. Photodynamic therapy for recurrent supratentorial gliomas. Semin Surg Oncol. 1995;11(5):346–354
  39. Muller PJ, Wilson BC. Photodynamic therapy for malignant newly diagnosed supratentorial gliomas. J Clin Laser Med Surg. 1996;14(5):263–270
  40. Stummer W, et al. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg. 2000;93(6):1003–1013
  41. Eljamel S. Photodynamic assisted surgical resection and treatment of malignant brain tumours technique, technology and clinical application. Photodiagn Photodyn Ther. 2004;1(1):93–98
  42. Kelly JF, Snell ME, Berenbaum MC. Photodynamic destruction of human bladder carcinoma. Br J Cancer. 1975;31(2):237–244
  43. Kelly JF, Snell ME. Hematoporphyrin derivative: a possible aid in the diagnosis and therapy of carcinoma of the bladder. J Urol. 1976;115(2):150–151
  44. Morton CA, et al. Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br J Dermatol. 2002;146(4):552–567
  45. Clark C, et al. Topical 5-aminolaevulinic acid photodynamic therapy for cutaneous lesions: outcome and comparison of light sources. Photodermatol Photoimmunol Photomed. 2003;19(3):134–141
  46. Ibbotson S, et al. Photodynamic therapy in dermatology: Dundee clinical and research experience. Photodiagn Photodyn Ther. 2004;1:211–223

PII: S1572-1000(05)00111-0

doi: 10.1016/S1572-1000(05)00111-0

Photodiagnosis and Photodynamic Therapy
Volume 2, Issue 4 , Pages 239-246 , December 2005

Article Tools